What Verge Genomics does
Verge Genomics is a biotechnology company applying AI and human genomics data to drug discovery, with a focus on neurodegenerative diseases. It develops treatments using its CONVERGE platform, an all-in-human, AI-powered drug discovery system that aims to identify disease causes and candidate drugs faster than conventional approaches.
Key capabilities
The company maintains a large proprietary multi-omics database derived from human tissue, which it uses to study disease biology without relying solely on animal or cell models. It combines machine learning with internal biology and chemistry platforms to move from research toward clinical candidates. Its lead programs address conditions including ALS, Parkinson's disease, and frontotemporal dementia.
Who it's for
Verge Genomics' work is aimed at patients with neurodegenerative diseases that have limited existing therapies, and at pharmaceutical and biotech partners seeking AI-driven drug discovery collaborations in the life sciences and healthcare sector.